Abivax SA Aktie

99,50 EUR -0,70 EUR -0,70 %

09.01.2026

BMN

91,13 CHF -1,49 CHF -1,61 %

09.01.2026

BRX

Abivax SA jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)

Jetzt loslegen

Direkt handeln

Bei einem anderen Broker handeln

Marktkap.7,78 Mrd. EUR

Div. Rendite0,00%

WKNA14UQC

ISINFR0012333284

SymbolAAVXF

Abivax SA Aktien News

Sortieren:Datum Meistgelesen

07.01.26EQS GroupEQS-News: Abivax Provides 2026 Corporate Outlook

18.12.25EQS GroupEQS-News: Abivax to be Added to Nasdaq Biotechnology Index

17.12.25EQS GroupEQS-News: Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings

WerbungAbivax SA-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

15.12.25EQS GroupEQS-News: Abivax Presents Third Quarter 2025 Financial Results

06.10.25EQS GroupEQS-News: Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies

05.10.25EQS GroupEQS-News: Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data

29.09.25EQS GroupEQS-News: Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting

23.09.25EQS GroupEQS-News: Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology (UEG) Meeting

12.09.25EQS GroupEQS-News: Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review

08.09.25EQS GroupEQS-News: Abivax Presents First Half 2025 Financial Results

25.07.25EQS GroupEQS-News: Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M)

24.07.25EQS GroupEQS-News: Abivax announces trading resumption of its ordinary shares on Euronext Paris

24.07.25EQS GroupEQS-News: Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares

24.07.25EQS GroupEQS-News: Abivax announces temporary trading halt of its ordinary shares on Euronext Paris

23.07.25EQS GroupEQS-News: Abivax Announces Launch of Public Offering

11.06.25EQS GroupEQS-News: Abivax Announces Results of its June 6, 2025 Annual General Meeting

02.06.25EQS GroupEQS-News: Abivax Presents First Quarter 2025 Financial Results

29.04.25EQS GroupEQS-News: Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis

22.04.25EQS GroupEQS-News: Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones

22.04.25EQS GroupEQS-News: Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors

26.03.25EQS GroupEQS-News: Abivax publishes financial reports with the French and U.S. securities regulatory agencies

24.03.25EQS GroupEQS-News: Abivax Announces Full Year 2024 Financial Results

21.02.25EQS GroupEQS-News: Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025

28.01.25EQS GroupEQS-News: Abivax Publishes 2025 Financial Calendar

23.01.25EQS GroupEQS-News: Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn’s and Colitis Organization 20th Annual Congress

09.01.25EQS GroupEQS-News: Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment

23.12.24EQS GroupEQS-News: Abivax Announces a Change to the Composition of its Board of Directors

19.11.24EQS GroupEQS-News: Abivax Establishes an At-the-Market (ATM) Program on Nasdaq

14.11.24EQS GroupEQS-News: Abivax presents third quarter 2024 key financial information

13.11.24EQS GroupEQS-News: Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax

07.10.24EQS GroupEQS-News: Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation

03.10.24EQS GroupEQS-News: Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn’s Disease

03.10.24EQS GroupEQS-News: Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance

26.09.24EQS GroupEQS-News: Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024

09.09.24EQS GroupEQS-News: Abivax presents first-half 2024 financial results

06.08.24EQS GroupEQS-News: Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment Milestone

15.07.24EQS GroupEQS-News: Abivax Provides Operational and Key Program Update

05.04.24EQS GroupEQS-News: Abivax reicht Finanzberichte bei der französischen und der US-amerikanischen Finanzmarktaufsicht ein

05.04.24EQS GroupEQS-News: Abivax publishes financial reports with the French and U.S. securities regulatory agencies

02.04.24EQS GroupEQS-News: Abivax reports 2023 financial results and operational update

Abivax SA News

Abivax SA News: auf dieser Seite finden Sie alle Abivax SA News und Nachrichten zur Abivax SA Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Abivax SA News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Abivax SA News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.